- Home
- INMB vs ATYR Comparison
INMB vs ATYR Comparison
Compare INMB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 79.2M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | INMB | ATYR |
|---|---|---|
| Price | $1.83 | $0.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.30 | ★ $8.75 |
| AVG Volume (30 Days) | 494.4K | ★ 2.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $50,000.00 | ★ $190,000.00 |
| Revenue This Year | $173.21 | N/A |
| Revenue Next Year | $12,733.99 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $0.64 |
| 52 Week High | $11.64 | $7.29 |
Technical Indicators
Market Signals| Indicator | INMB | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 41.71 |
| Support Level | $1.75 | $0.70 |
| Resistance Level | $2.30 | $0.83 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 38.82 | 26.75 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.